Biotronik names Mayo Clinic cardiologist as 1st CMO

Berlin-based CV tech company Biotronik has hired cardiologist David Hayes, MD, as its first chief medical officer, the company announced Jan. 27.

As CMO, Hayes—who previously worked with Mayo Clinic for more than four decades—will reportedly oversee the development of Biotronik’s heart solutions “with a focus on advancing unique, proven innovations that help physicians and health systems deliver on their commitment to patient care.” At Mayo Clinic, the board-certified cardiologist worked as a professor of cardiovascular medicine, physician administrator and, most recently, medical director of the Mayo Clinic Care Network.

“This is an opportunity for me to drive change and create positive patient impact from a very different perspective,” Hayes said in a statement. “As the Chief Medical Officer of Biotronik, Inc., I have assumed a role rooted in collaboration, understanding and action. We’re ready to challenge norms and shake things up.”

Biotronik is headquartered in Germany and boasts an extensive portfolio of FDA-cleared and -approved devices, including the ultra-thin Orsiro drug-eluting stent and the BIOMONITOR III arrhythmia detector.

“Cardiology is an area of healthcare that should always be evolving and advancing,” Hayes said. “We’re making sure that happens. I’m personally committed to ensuring physicians know they have a trusted partner in Biotronik."

""

After graduating from Indiana University-Bloomington with a bachelor’s in journalism, Anicka joined TriMed’s Chicago team in 2017 covering cardiology. Close to her heart is long-form journalism, Pilot G-2 pens, dark chocolate and her dog Harper Lee.

Around the web

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.

The imaging manufacturer expects to spend between $227 million and $340 million on tariff mitigation efforts, leaders said Wednesday.